BDBM352400 5′-(7-Cyclopropyl-7H-imidazo[4,5-c]pyridazin-4-yl)-2′-fluoro-N-methylbiphenyl-4-carboxamide::US9802945, 11
SMILES: CNC(=O)c1ccc(cc1)-c1cc(ccc1F)-c1cnnc2n(cnc12)C1CC1
InChI Key: InChIKey=LBUUNEXUAXYFLF-UHFFFAOYSA-N
Data: 1 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gamma-aminobutyric acid receptor subunit alpha-2 (Homo sapiens (Human)) | BDBM352400 (5′-(7-Cyclopropyl-7H-imidazo[4,5-c]pyridazin...) | PDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 20.5 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Limited US Patent | Assay Description The affinity of the test compounds was determined by radioligand competition binding assay, using the known compound [3H]Ro-15-1788 (Flumazenil) (Per... | US Patent US9802945 (2017) BindingDB Entry DOI: 10.7270/Q2NP26JT | |||||||||||
More data for this Ligand-Target Pair |